Straits Times Index
3,303.66 +12.96 (+0.39%) S&P 500
5,221.42 -1.26 (-0.02%) Dow
39,431.51 -81.33 (-0.21%) Nasdaq
16,388.24 +47.37 (+0.29%) Bitcoin USD
63,101.56 +1,749.52 (+2.85%) CMC Crypto 200
1,296.51 +36.30 (+2.88%)
NVO Jan 2026 85.000 call
| Previous close | 48.65 |
| Open | 48.65 |
| Bid | 55.30 |
| Ask | 59.00 |
| Strike | 85.00 |
| Expiry date | 2026-01-16 |
| Day's range | 48.65 - 48.65 |
| Contract range | N/A |
| Volume | |
| Open interest | 56 |
GlobeNewswireNovo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 people. The trial investigated the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment in people aged 12 years or older with haemophilia A with or without inhibitors. The trial achieved its co-primary endp
- Reuters
UPDATE 2-Denmark faces Wegovy shortage due to rising demand
Denmark faces a supply shortage for two doses of Novo Nordisk's Wegovy weight-loss drug in the coming months due to rising demand, the Danish Medicines Agency said on Monday. The hugely popular Wegovy is given by weekly injection and belongs to a class of drugs known as GLP-1 agonists originally developed to treat type 2 diabetes. There will be a shortage of Novo Nordisk's Wegovy Flextouch 1 milligram pen from late May to mid-June, the Danish medicines agency said in a statement.
